Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Bocconi University, Milan, Italy.
University of Warwick, School of Engineering, Coventry, UK.
Int J Health Policy Manag. 2021 Feb 1;10(2):102-105. doi: 10.15171/ijhpm.2020.18.
In this commentary, we discuss early stage assessments of innovative medical technologies both in terms of methods applied as well as their use in healthcare decision-making. We argue that cost-effectiveness alone may be too reductive if taken as the only decision rule, and it would benefit from being used within a broader evaluation framework. We discuss innovative methods which may contribute to better estimate the potential costs and consequences of a technology in the absence of solid clinical data, as frequently the case in early assessments. Finally, we comment on the potential synergies which may take place should early economic models be used not only by technology developers alone but as a negotiating base during early dialogues with health technology assessment (HTA) bodies.
在这篇评论中，我们讨论了创新医疗技术的早期评估，既包括所应用的方法，也包括其在医疗保健决策中的应用。我们认为，如果仅将成本效益作为唯一的决策规则，可能过于简化，如果将其应用于更广泛的评估框架中，将会受益。我们讨论了一些创新的方法，这些方法可能有助于在缺乏可靠临床数据的情况下更好地估计技术的潜在成本和后果，这种情况在早期评估中经常出现。最后，我们评论了如果早期经济模型不仅被技术开发者使用，而且作为与健康技术评估（HTA）机构早期对话的谈判基础，可能会产生的潜在协同作用。
